Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

Under such a scenario as you propose, shouldn’t

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
sentiment_stocks Member Profile
Member Level 
Followed By 80
Posts 9,089
Boards Moderated 1
Alias Born 03/29/14
160x600 placeholder
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/18/2019 6:02:10 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 7/17/2019 5:24:27 PM
Biotech Companies with Recent and Potential Near-Term Catalysts InvestorsHub NewsWire - 7/15/2019 8:15:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/28/2019 12:11:21 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2019 5:24:36 PM
Annual Report (10-k) Edgar (US Regulatory) - 4/2/2019 5:23:33 PM
Notification That Annual Report Will Be Submitted Late (nt 10-k) Edgar (US Regulatory) - 3/19/2019 5:19:39 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2019 3:33:33 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2019 3:20:35 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/7/2019 5:26:54 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 1/8/2019 6:04:56 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/20/2018 4:18:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/11/2018 4:17:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/28/2018 5:28:53 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/23/2018 1:44:13 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/16/2018 5:38:07 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 11/15/2018 3:15:58 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/13/2018 4:49:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2018 4:24:26 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/14/2018 4:52:44 PM
sentiment_stocks Member Level  Monday, 06/10/19 10:58:08 AM
Re: AVII77 post# 232419
Post # of 236926 
Under such a scenario as you propose, shouldn’t then the patients who were in the screening pipeline have also been informed of this “low likelihood” of answering that same hypothetical question of whether their PFS would be extended by entering the main arm of the trial? I would think that those patients would be entitled to know such a detail before entering the main arm of the trial. In fact, I’ll go a step further and say all patients should be told that if it were the case.

And yet, no such warning was given them.

Additionally, if OS is an independently measured endpoint as Dr Bosch claims it is, then if there was still a high likelihood that answering the more important question of whether OS would be extended was still in play, I’d think putting a halt on enrollment in the trial would be, well, an almost naughty thing to do.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist